JPMorgan Chase & Co. Reiterates Overweight Rating for AstraZeneca (LON:AZN)

JPMorgan Chase & Co. reissued their overweight rating on shares of AstraZeneca (LON:AZN) in a report published on Wednesday, MarketBeat.com reports.

Several other analysts also recently issued reports on AZN. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. Berenberg Bank reissued a “buy” rating and set a GBX 140 ($1.77) price objective on shares of AstraZeneca in a report on Monday, January 27th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, AstraZeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 7,542.80 ($95.30).

AstraZeneca Trading Up 1.0 %

Shares of LON:AZN opened at £117.08 ($147.92) on Wednesday. The stock has a market capitalization of £225.27 billion, a PE ratio of 32.09, a P/E/G ratio of 0.86 and a beta of 0.17. The firm has a fifty day moving average price of £109.99 and a 200 day moving average price of £114.67. AstraZeneca has a 1 year low of GBX 9,670 ($122.17) and a 1 year high of £133.88 ($169.15). The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.